Acceleron Pharma (XLRN) Misses Q2 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. VZ
9. LMT
10. SPY

Go back to Acceleron Pharma (XLRN) Misses Q2 EPS by 14c

Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results

August 3, 2017 4:07 PM EDT

- Completed full enrollment of luspatercept MEDALIST and BELIEVE Phase 3 trials -

- Presented updated luspatercept Phase 2 results in patients with MDS and beta-thalassemia receiving treatment for up to two years -

- Treated first patient in ACE-083 Phase 2 study in Charcot-Marie-Tooth disease -

- Upcoming R&D Day on September 19th to highlight Accelerons pipeline and strategic focus -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a... More